SCHEMBL2985222

SCHEMBL2985222

COc1ccccc1CC(=O)Nc1ccc(C(=O)CN2C(=O)C(c3ccccc3)(c3ccccc3)N=C2C)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.47
GPR55 Q9Y2T6 1/20 0.47
MEN1 O00255 8/20 0.46
KMT2A Q03164 8/20 0.46
TSHR P16473 1/20 0.46
KLK7 P49862 1/20 0.45
MAPT P10636 5/20 0.44
LMNA P02545 3/20 0.44
USP2 O75604 3/20 0.44
HSD17B10 Q99714 3/20 0.44
ALDH1A1 P00352 2/20 0.44
HPGD P15428 1/20 0.44
MAPK1 P28482 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
HTT P42858 1/20 0.43
NPY2R P49146 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2978544 0.91 KMT2A (0.44) KDM4EMEN1KMT2ATSHRMAPT
SCHEMBL2978004 0.89 KMT2A (0.43) MEN1KMT2AMAPTALDH1A1
SCHEMBL2982704 0.86 MAPT (0.52) KDM4EMEN1KMT2AMAPTLMNA
SCHEMBL2975095 0.84 KDM4E (0.46) KDM4EGPR55MEN1KMT2ATSHR
SCHEMBL2984383 0.80 TAS2R8 (0.42) LMNANPY2R
SCHEMBL3655095 0.80 MEN1 (0.59) MEN1KMT2AMAPTALDH1A1
SCHEMBL2986897 0.78 SMN1; SMN2 (0.50) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL2985753 0.78 BACE1 (0.46) KMT2AMAPTSMN1; SMN2CYP3A4CYP2C9
SCHEMBL2983179 0.76 NPC1 (0.49) KDM4EMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL2989532 0.76 BACE1 (0.50) MAPTSMN1; SMN2CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7786155-B2 Organic compounds NOVARTIS AG (CH) 2010-08-31 US claimed
US-7786155-B2 Organic compounds NOVARTIS AG (CH) 2010-08-31 US disclosed
EP-2212295-A2 4-PHENYL-5-OXO-IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEROF Novartis AG (CH) 2010-08-04 EP disclosed
WO-2009050201-A2 4-PHENYL-5-OXO-IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEROF NOVARTIS AG (CH) 2009-04-23 WO disclosed
US-20090099244-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099244-A1 ORGANIC COMPOUNDS SLCO4C1, SLC10A6, SLCO1B1 KDM4E 2393/4885GPR55 3571/4885MEN1 235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.